Development of a SARS-CoV-2 vaccine

NIH Pandemic-Era Grants

Pandemic Era Grants

2022

↗ Live URL (may be dead)

Document text

Principal Investigator: Bernard  Moss
Organization: NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES
Fiscal Year: 2022
Award: $50,856
Funding agency: National Institute of Allergy and Infectious Diseases

We constructed a panel of recombinant MVAs that express unmodified or modified SARS-CoV-2 spike (S) protein. Intramuscular injection of mice with the rMVAs induced antibodies, which neutralized a pseudovirus in vitro and upon passive transfer protected hACE2 transgenic mice from lethal infection with SARS-CoV-2, as well as S-specific CD3+CD8+IFNg+ T cells. Antibody boosting occurred following a second rMVA or adjuvanted purified RBD protein. Immunity conferred by a single vaccination of transgenic hACE2 mice prevented morbidity and weight loss upon intranasal infection with SARS-CoV-2 three or seven weeks later. One or two rMVA vaccinations also prevented detection of infectious SARS-CoV-2 and subgenomic viral mRNAs in the lungs and greatly reduced induction of cytokine and chemokine mRNAs. In contrast, intranasal administration of the vaccine prevented or rapidly eliminated SARS-CoV-2 from the nose and lungs within 2 days.

Terms: <2019 novel corona virus><2019 novel coronavirus><2019-nCoV><2019-nCoV S protein><2019-nCoV spike glycoprotein><2019-nCoV spike protein><2019-nCoV vaccine><Adjuvant><Animal Model><Animal Models and Related Studies><Antibodies><Attenuated><Body Weight decreased><CD3><CD3 Antigens><CD3 Complex><CD3 molecule><CD8><CD8B><CD8B1><CD8B1 gene><COVID-19 S protein><COVID-19 spike glycoprotein><COVID-19 spike protein><COVID-19 vaccine><COVID-19 virus><COVID19 S protein><COVID19 spike glycoprotein><COVID19 spike protein><COVID19 vaccine><COVID19 virus><Cell Body><Cells><Chemotactic Cytokines><Clinical><CoV-2><CoV2><Detection><Development><Goals><Homologous Chemotactic Cytokines><Human><Immunity><In Vitro><Infection><Intercrines><Intramuscular Injections><Intranasal Administration><Intranasal Drug Administration><LYT3><Lung><Lung Respiratory System><Messenger RNA><Mice><Mice Mammals><Modern Man><Modified Vaccinia Ankara><Modified Vaccinia Virus Ankara><Morbidity><Morbidity - disease rate><Murine><Mus><Nasal><Nasal Passages Nose><Nose><OKT3 antigen><Poxvirus officinale><Proteins><Recombinant modified vaccinia virus Ankara><Recombinants><Respiratory System, Nose, Nasal Passages><SARS corona virus 2><SARS-CO-V2><SARS-COVID-2><SARS-CoV-2><SARS-CoV-2 S protein><SARS-CoV-2 spike glycoprotein><SARS-CoV-2 spike protein><SARS-CoV-2 vaccine><SARS-CoV2><SARS-CoV2 S protein><SARS-CoV2 spike glycoprotein><SARS-CoV2 spike protein><SARS-CoV2 vaccine><SARS-associated corona virus 2><SARS-associated coronavirus 2><SARS-coronavirus-2><SARS-coronavirus-2 vaccine><SARS-related corona virus 2><SARS-related coronavirus 2><SARSCoV2><SIS cytokines><Severe Acute Respiratory Coronavirus 2><Severe Acute Respiratory Distress Syndrome CoV 2><Severe Acute Respiratory Distress Syndrome Corona Virus 2><Severe Acute Respiratory Distress Syndrome Coronavirus 2><Severe Acute Respiratory Syndrome CoV 2><Severe Acute Respiratory Syndrome CoV 2 vaccine><Severe Acute Respiratory Syndrome-associated coronavirus 2><Severe Acute Respiratory Syndrome-related coronavirus 2><Severe acute respiratory syndrome associated corona virus 2><Severe acute respiratory syndrome corona virus 2><Severe acute respiratory syndrome coronavirus 2><Severe acute respiratory syndrome coronavirus 2 S protein><Severe acute respiratory syndrome coronavirus 2 spike glycoprotein><Severe acute respiratory syndrome coronavirus 2 spike protein><Severe acute respiratory syndrome coronavirus 2 vaccine><Severe acute respiratory syndrome related corona virus 2><Smallpox Vaccine><T-Cells><T-Lymphocyte><T3 Antigens><T3 Complex><T3 molecule><Testing><Transgenic Mice><Transgenic Organisms><Vaccination><Vaccines><Vaccinia><Vaccinia virus><Viral><Weight Loss><Weight Reduction><Wuhan coronavirus><base><body weight loss><chemoattractant cytokine><chemokine><corona virus disease 2019 vaccine><coronavirus disease 2019 S protein><coronavirus disease 2019 spike glycoprotein><coronavirus disease 2019 spike protein><coronavirus disease 2019 vaccine><coronavirus disease 2019 virus><coronavirus disease-19 vaccine><coronavirus disease-19 virus><cytokine><developmental><engineered MVA><hCoV19><intramuscular drug administration><mRNA><model of animal><model organism><nCoV2><pathogen><prevent><preventing><pulmonary><rMVA><recombinant MVA><recombinant vaccinia virus><small pox vaccine><thymus derived lymphocyte><transgenic><vaccine against 2019-nCov><vaccine against SARS-CoV-2><vaccine against SARS-CoV2><vaccine against SARS-coronavirus-2><vaccine against Severe Acute Respiratory Syndrome CoV 2><vaccine against Severe acute respiratory syndrome coronavirus 2><vaccine for novel coronavirus><wt-loss>